Endocrinology Fellowship Program, East Carolina University, Brody School of Medicine, Greenville, North Carolina.
Internal Medicine Residency Program, Gwinnett Medical Center, Lawrenceville, Georgia.
Cancer Cytopathol. 2018 Oct;126(10):881-888. doi: 10.1002/cncy.22054. Epub 2018 Oct 18.
The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) was created to establish a standard terminology regarding thyroid nodules that can be shared between endocrinologists, pathologists, radiologists, and surgeons. Since its inception and use in 2009, multiple large hospitals and academic institutions have performed retrospective studies to compare their classification rates, specifically those of atypia of undetermined significance (AUS) and follicular lesion of undetermined significance (FLUS), with the recommended rates created by the National Cancer Institute. The current study compared AUS/FLUS rates at a private suburban endocrine practice with those of previous publications from large institutions and the rates established by the National Cancer Institute.
Charts from 893 patients with fine-needle aspiration (FNA) performed in 2015 were reviewed. Data specific to thyroid aspirates classified as AUS/FLUS were organized into whether patients underwent surgery, underwent subsequent repeat FNA, or required continued observation. These results then were calculated to reveal the rate of malignancy in the AUS/FLUS category with surgical pathology in the study institution.
A total of 893 patients underwent FNA, with 43 patients (4.82%) shown to have AUS/FLUS. A total of 21 patients proceeded to undergo thyroidectomy or lobectomy, with 7 patients (33.3%) found to have papillary or follicular thyroid carcinoma.
The rate of use of the AUS/FLUS category for thyroid nodules examined at the study institution was found to be within the recommended range set forth by TBSRTC. However, the malignancy rates on histopathology in the study institution were found to be higher than the new proposed malignancy rates from TBSRTC published in 2017. This finding is comparable to those of multiple other community and academic institutions performed prior to and after institution of the new guidelines.
贝塞斯达甲状腺细胞病理学报告系统(Bethesda System for Reporting Thyroid Cytopathology,TBSRTC)的创立是为了建立一个关于甲状腺结节的标准术语,以便内分泌学家、病理学家、放射科医生和外科医生能够共享。自 2009 年创立并使用以来,多家大型医院和学术机构已经进行了回顾性研究,以比较其分类率,特别是不明确意义的非典型性(AUS)和滤泡性病变不明确意义(FLUS)的分类率,与国家癌症研究所(National Cancer Institute)推荐的分类率进行比较。本研究将一家私人郊区内分泌诊所的 AUS/FLUS 比率与之前大型机构的出版物和国家癌症研究所建立的比率进行了比较。
对 2015 年进行的 893 例细针抽吸(fine-needle aspiration,FNA)患者的图表进行了回顾。将甲状腺抽吸物分类为 AUS/FLUS 的特定数据整理为患者是否接受手术、是否进行后续重复 FNA 或需要继续观察。然后计算这些结果,以显示研究机构手术病理中 AUS/FLUS 类别中的恶性肿瘤发生率。
共有 893 例患者接受了 FNA,其中 43 例(4.82%)显示为 AUS/FLUS。共有 21 例患者接受了甲状腺切除术或叶切除术,其中 7 例(33.3%)发现患有乳头状或滤泡状甲状腺癌。
研究机构检查的甲状腺结节使用 AUS/FLUS 类别的比率被发现处于 TBSRTC 规定的推荐范围内。然而,研究机构的组织病理学恶性肿瘤率被发现高于 2017 年 TBSRTC 发布的新建议恶性肿瘤率。这一发现与新指南实施前后多家其他社区和学术机构的研究结果相似。